Oncotarget is a medical journal that covers all aspects of oncology and is aimed at educating the lay man on issues to do with medicine. The journal was founded way back in 2010 by a group of journalists. The journal has two editors in chief who are Mikhail Blagosklonny and Andrei V. Gudkov. The journal initially started off with a publication per week but this has now changed and they are publishing two articles per week now and they are published online for free.
The main purpose of the journals are basically to make access of medical journals easily available. In return, this makes research on medicine quite wide, hence, making discoveries of medicinal issues very easy and convenient. Oncotarget’s main aim is to help out researchers in terms of bettering the world of science. They are hell bent on ensuring that diseases are kicked out completely in the world so that it can be a better place to live in.
Having been in the business for a while, Oncotarget is now looking to launch a whole new section on topics that are not just about oncology. The topics they are focusing now of late are those of cardiology, microbiology, and pharmacology.
In October, this year, Integragen which is a company that deals in the transformation of biological data into data that can be used in oncology, announced that it published an article on Oncotarget concerning the analysis of tumors in various patients.
The paper is titled “Association between miR-31- 3p expression and cetuximab efficacy in patients with KRAS wild-type metastatic colorectal cancer: a post-hoc analysis of the New EPOC trial” and simply explains the relationship that exists between miR-31-3p expression and the efficacy of anti-EGFR treatment. The paper explains that expression levels of miR-31-3p in patients who are diagnosed with metastatic colorectal cancer can be used to help the affected benefit from anti-EGFR therapy.
The Reuters Thompson group rewarded Oncotarget in 2011 as the best journal and ever since this award, no other journal has been able to kick out Oncotarget from this position. This is because the journal makes it easy for everyone to read their articles even if they are not in the medicinal field.